STOCKHOLM, March 15, 2019 /PRNewswire/ -- Moberg Pharma
AB (publ) ("Moberg Pharma" or the "Company") (OMX: MOB) today held
an Extraordinary General Meeting in the Company's premises in
Bromma. The Extraordinary General Meeting resolved as set out
below.
Approval of the transaction
The Extraordinary General Meeting resolved, in accordance with
the proposal of the Board of Directors, to approve the sale of the
entire share capital in the Company's subsidiary, MPJ OTC AB, and
all of the units in Moberg Pharma North America, LLC, including the
Company's entire global consumer health business comprising both
direct and distributor sales under the over-the-counter brands
Kerasal®, Kerasal Nail®, New Skin®, Dermoplast®, Domeboro®, Emtrix®
and Zanmira®, and all assets and liabilities related to such
business to RoundTable Healthcare Partners and Signet Healthcare
Partners on the terms further described in the Board of Directors'
proposal (the "Transaction").
Conversion of the Company's financial year
The Extraordinary General Meeting resolved, in accordance with
the proposal of the Board of Directors, to convert the Company's
financial year from calendar year to broken financial year, 1
July–30 June and to make thereto related amendments to the articles
of association, whereby the last day of the current financial year
will be 30 June 2019.
Instating of a new share class
The Extraordinary General Meeting resolved, in accordance with
the proposal of the Board of Directors, to introduce a new share
class; series B shares and to make thereto related amendments to
the articles of association. The series B shares will, under
certain conditions as stated in the articles of association, be
redeemable at the quota value and convertible into ordinary shares,
but will otherwise have the same rights as the Company's ordinary
shares.
Authorization to issue redeemable and convertible series B
shares
The Extraordinary General Meeting resolved, in accordance with
the proposal of the Board of Directors, to authorize the Board of
Directors to on one or several occasions before the next Annual
General Meeting, resolve to issue new redeemable and convertible
series B shares, with deviation from the shareholders' pre-emptive
rights on the terms further described in the Board of Directors'
proposal.
Authorization to issue warrants
The Extraordinary General Meeting resolved, in accordance with
the proposal of the Board of Directors, to authorize the Board of
Directors to on one or several occasions before the next Annual
General Meeting, resolve to issue warrants, with deviation from the
shareholders' pre-emptive rights on the terms further described in
the Board of Directors' proposal.
Election of Andrew B. Hochman
as member of the Board of Directors
The Extraordinary General Meeting resolved, in accordance with
the proposal of the Board of Directors, that the Board of Directors
shall have six members and to elect Andrew
B. Hochman as ordinary member of the Board of Directors for
a period from and including the day when closing of the Transaction
has occurred, until the end of the next Annual General Meeting.
CONTACT:
For additional information, please contact:
Peter Wolpert, CEO
phone: Sweden: +46-707-35-7135,
US: +1-908-432-2203
e-mail: peter.wolpert@mobergpharma.se
Anna Ljung, CFO
phone: +46-707-66-6030
e-mail: anna.ljung@mobergpharma.se
About this
information
This information is information that Moberg Pharma AB (publ) is
obliged to make public pursuant to the EU Market Abuse Regulation.
The information was submitted for publication, through the contact
persons set out above, at 5.00 p.m.
(CET) on March 15th, 2019.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/moberg-pharma/r/bulletin-from-moberg-pharma-s-extraordinary-general-meeting-15-march-2019,c2763248
The following files are available for download:
|
https://mb.cision.com/Main/1662/2763248/1008121.pdf
|
Bulletin from Moberg
Pharma’s Extraordinary General Meeting 15 March 2019
|
View original
content:http://www.prnewswire.com/news-releases/bulletin-from-moberg-pharmas-extraordinary-general-meeting-15-march-2019-300813232.html
SOURCE Moberg Pharma